UMPS [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= UMPS =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: UMPS
  * **<color #00a2e8>Official Name</color>**: uridine monophosphate synthetase
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7372|7372]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P11172|P11172]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=UMPS&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20UMPS|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/613891|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a uridine 5'-monophosphate synthase. The encoded protein is a bifunctional enzyme that catalyzes the final two steps of the de novo pyrimidine biosynthetic pathway. The first reaction is carried out by the N-terminal enzyme orotate phosphoribosyltransferase which converts orotic acid to orotidine-5'-monophosphate. The terminal reaction is carried out by the C-terminal enzyme OMP decarboxylase which converts orotidine-5'-monophosphate to uridine monophosphate. Defects in this gene are the cause of hereditary orotic aciduria. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2010]. 
  * **<color #00a2e8>UniProt Summary</color>**: N/A

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|OMPdecase|
|Pribosyltran|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|orotate phosphoribosyltransferase activity|
|orotidine-5-phosphate decarboxylase activity|
|de novo UMP biosynthetic process|
|de novo pyrimidine nucleobase biosynthetic process|
|pyrimidine nucleobase biosynthetic process|
|UMP biosynthetic process|
|pyrimidine ribonucleoside monophosphate biosynthetic process|
|UMP metabolic process|
|pyrimidine ribonucleoside monophosphate metabolic process|
|pyrimidine nucleoside monophosphate biosynthetic process|
|pyrimidine nucleoside biosynthetic process|
|pyrimidine nucleoside monophosphate metabolic process|
|nucleobase biosynthetic process|
|pyrimidine ribonucleotide biosynthetic process|
|pyrimidine nucleobase metabolic process|
|pyrimidine ribonucleotide metabolic process|
|ribonucleoside monophosphate biosynthetic process|
|pyrimidine nucleoside metabolic process|
|nucleoside biosynthetic process|
|nucleobase metabolic process|
|glycosyl compound biosynthetic process|
|nucleoside monophosphate biosynthetic process|
|lactation|
|pyrimidine nucleotide biosynthetic process|
|ribonucleoside monophosphate metabolic process|
|pyrimidine-containing compound biosynthetic process|
|pyrimidine nucleotide metabolic process|
|nucleoside monophosphate metabolic process|
|body fluid secretion|
|pyrimidine-containing compound metabolic process|
|nucleobase-containing small molecule biosynthetic process|
|nucleoside metabolic process|
|mammary gland development|
|glycosyl compound metabolic process|
|ribonucleotide biosynthetic process|
|ribose phosphate biosynthetic process|
|female pregnancy|
|multi-multicellular organism process|
|nucleotide biosynthetic process|
|nucleoside phosphate biosynthetic process|
|ribonucleotide metabolic process|
|ribose phosphate metabolic process|
|cellular response to drug|
|gland development|
|nucleotide metabolic process|
|nucleoside phosphate metabolic process|
|regulation of body fluid levels|
|organophosphate biosynthetic process|
|nucleobase-containing small molecule metabolic process|
|small molecule biosynthetic process|
|carbohydrate derivative biosynthetic process|
|organophosphate metabolic process|
|multi-organism reproductive process|
|response to drug|
|carbohydrate derivative metabolic process|
|nucleobase-containing compound biosynthetic process|
|secretion|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|organic cyclic compound biosynthetic process|
|organonitrogen compound biosynthetic process|
|reproductive process|
|reproduction|
|cellular nitrogen compound biosynthetic process|
|small molecule metabolic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='default' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp82|Torin1 0.08μM R02 exp82]]|-3.24|
|[[:results:exp359|FK-506 30μM R07 exp359]]|-2.64|
|[[:results:exp216|Erlotinib 10μM R05 exp216]]|-2.48|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-2.22|
|[[:results:exp363|GSK-J4 1-1.25μM to day4 R07 exp363]]|-2.15|
|[[:results:exp419|Tunicamycin 0.04 to 0.075μM  on day4 R07 exp419]]|-2.11|
|[[:results:exp130|JQ1 0.01μM R03 exp130]]|-2.1|
|[[:results:exp230|Epigallocatechin gallate 20μM R05 exp230]]|-2.04|
|[[:results:exp308|Rapamycin 2μM plus FK-506 5μM R07 exp308]]|-1.98|
|[[:results:exp256|HMS-I1 10μM R06 exp256]]|-1.92|
|[[:results:exp73|LJH685 5μM R02 exp73]]|-1.91|
|[[:results:exp330|5-Azacytidine 2μM R07 exp330]]|-1.89|
|[[:results:exp358|FK-506 5μM R07 exp358]]|-1.89|
|[[:results:exp120|Dimethyl-Sulfoxide 1pc R03 exp120]]|-1.84|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|-1.82|
|[[:results:exp418|Tunicamycin 0.04μM R07 exp418]]|-1.82|
|[[:results:exp75|MK-1775 0.32μM R02 exp75]]|-1.8|
|[[:results:exp269|Bisphenol A 100μM R06 exp269]]|-1.76|
|[[:results:exp262|Alda-1 10μM R06 exp262]]|-1.75|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|-1.7|
|[[:results:exp64|Nocodazole 0.2μM R02 exp64]]|1.7|
|[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|1.72|
|[[:results:exp140|Nicotinate 1000μM R03 exp140]]|1.79|
|[[:results:exp237|NN-Diethyl-meta-toluamide 100μM R05 exp237]]|1.81|
|[[:results:exp243|S-trityl-L-cysteine 0.5μM R05 exp243]]|1.85|
|[[:results:exp1|5-Fluorouracil 2μM R00 exp1]]|1.95|
|[[:results:exp125|GSK461364A 0.005μM R03 exp125]]|2|
|[[:results:exp293|Myriocin 25μM R06 exp293]]|2|
|[[:results:exp219|A-395N 10μM R05 exp219]]|2.23|
|[[:results:exp355|Dinaciclib 0.007μM R07 exp355]]|3.37|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
No correlation found to any other genes in chemogenomics.
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 91/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|3/28|
|blood|14/28|
|bone|2/26|
|breast|8/33|
|central nervous system|1/56|
|cervix|0/4|
|colorectal|2/17|
|esophagus|1/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|4/21|
|liver|1/20|
|lung|5/75|
|lymphocyte|5/16|
|ovary|0/26|
|pancreas|5/24|
|peripheral nervous system|1/16|
|plasma cell|4/15|
|prostate|0/1|
|skin|3/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|1/22|
|urinary tract|2/29|
|uterus|1/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 9
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.4 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='UMPS Expression in NALM6 Cells: 6.4'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>